Evidence map›Paper›PMID 37099136›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015-2020.

Lia Gvinjilia, Davit Baliashvili, Shaun Shadaker, Francisco Averhoff, Levan Kandelaki, Maia Kereselidze, Tengiz Tsertsvadze, Nikoloz Chkhartishvili, Maia Butsashvili, David Metreveli and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lia GvinjiliaEastern Europe and Central Asia Regional Office, Centers for Disease Control and Prevention, Tbilisi, Georgia.
Davit BaliashviliThe Task Force for Global Health, Tbilisi, Georgia.ORCID 0000-0001-8390-3325
Shaun ShadakerDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Francisco AverhoffDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Levan KandelakiDepartment of Medical Statistics, National Center for Disease Control and Public Health, Tbilisi, Georgia.
Maia KereselidzeDepartment of Medical Statistics, National Center for Disease Control and Public Health, Tbilisi, Georgia.
Tengiz TsertsvadzeClinic "Hepa," Tbilisi, Georgia.
Nikoloz ChkhartishviliInfectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia.
Maia ButsashviliHealth Research Union and Clinic NeoLab, Tbilisi, Georgia.
David MetreveliClinic "Mrcheveli," Tbilisi, Georgia.
Amiran GamkrelidzeDepartment of Medical Statistics, National Center for Disease Control and Public Health, Tbilisi, Georgia.
Paige A ArmstrongDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundMortality related to hepatitis C virus (HCV) infection is a key indicator for elimination. We assessed the impact of HCV infection and treatment on mortality in the country of Georgia during 2015-2020.

methodsWe conducted a population-based cohort study using data from Georgia's national HCV Elimination Program and death registry. We calculated all-cause mortality rates in 6 cohorts: (1) Negative for anti-HCV; (2) anti-HCV positive, unknown viremia status; (3) current HCV infection and untreated; (4) discontinued treatment; (5) completed treatment, no sustained virologic response (SVR) assessment; (6) completed treatment and achieved SVR. Cox proportional hazards models were used to calculate adjusted hazards ratios and confidence intervals. We calculated the cause-specific mortality rates attributable to liver-related causes.

resultsAfter a median follow-up of 743 days, 100 371 (5.7%) of 1 764 324 study participants died. The highest mortality rate was observed among HCV infected patients who discontinued treatment (10.62 deaths per 100 PY, 95% confidence interval [CI]: 9.65, 11.68), and untreated group (10.33 deaths per 100 PY, 95% CI: 9.96, 10.71). In adjusted Cox proportional hazards model, the untreated group had almost 6-times higher hazard of death compared to treated groups with or without documented SVR (adjusted hazard ratio [aHR] = 5.56, 95% CI: 4.89, 6.31). Those who achieved SVR had consistently lower liver-related mortality compared to cohorts with current or past exposure to HCV.

conclusionsThis large population-based cohort study demonstrated the marked beneficial association between hepatitis C treatment and mortality. The high mortality rates observed among HCV infected and untreated persons highlights the need to prioritize linkage to care and treatment to achieve elimination goals.

Indexed as

Hepatitis CHepatitis C, ChronicAntiviral AgentsCohort StudiesGeorgiaHepacivirusHumansAntiviral Agents

Identifiers

PMID37099136
PMCPMC10527899

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.